This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kell, P. Articles by Ralph, D. Search for Related Content Social Bookmarking                         What's this?

Apomorphine SL in the treatment of erectile dysfunction

The Archway Sexual Health Clinic, Whittington Hospital, Highgate Hill, London, N19 5NF, UK, Pdkell{at}hotmail.com

John Dean

The Archway Sexual Health Clinic, Whittington Hospital, Highgate Hill, London, N19 5NF, UK

David Ralph

The Archway Sexual Health Clinic, Whittington Hospital, Highgate Hill, London, N19 5NF, UK

Men with erectile dysfunction (ED) have a high incidence of comorbid cardiovascular disease and diabetes. Additionally, some drugs used to treat cardiovascular disease have been implicated as contributors to ED. Sublingual (SL) apomorphine (Uprima^®), a compound with D₂-like dopamine receptor agonist effects, has a rapid onset of action, resulting in erectile response within 10 minutes of dosing in some patients (median onset of effect is 18—19 minutes). Apomorphine SL improves erectile function in men with mild-to-moderate ED and is well tolerated in patients with diabetes and/or cardiovascular disease.

Key Words: apomorphine SL • cardiovascular disease • diabetes • erectile dysfunction.

References

• Jardin A., Wagner G., Khour S. et al. Recommendations of the First International Consultation on Erectile Dysfunction. In: Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen R (eds.). Erectile Dysfunction. Plymouth, UK, Plymbridge Distributors Ltd, 2000;711-26.
• Feldman HA, Goldstein I., Hatzichristou DG, Krane RJ, McKinlay JB Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:1:54-61.[Web of Science][Medline] [Order article via Infotrieve]
• NIH Concensus Conference on Impotence. JAMA 1993;270:83-90.[Abstract/Free Full Text]
• Chew KK, Earle CM, Stuckey BGA, Jamrozik KD, Dhaliwal SS, Keogh EJ Erectile dysfunction in general medical practice. A study in Perth, Australia. IJIR 1997;(suppl 1):S36(abstract A17).
• Greenstein A., Chen J., Miller H., Matzkin H., Villa Y., Braf Z. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997;9:123-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pritzker MR The penile stress test: a window to the hearts of man? 72nd Proceedings of the American Heart Association 1999;(abstract 104561).
• Roumeguere T., Bollens R., Wespes E., Fourmarier M., Bialek D., Schulman C. Prevalence of hyperlipidemia and risk of coronary heart disease in a population with erectile dysfunction. J Urol 2001;165:S170-S171.700.
• Cheitlin MD, Hutter AM, Brindis RG et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 1999;33:278-82.
• Meinhardt W., Kropman RF, Vermeij P., Nijeholt AA, Zwartendijk J. The influence of medication on erectile function. Int J Impot Res 1997;9:17-26.[Medline] [Order article via Infotrieve]
• Dey J., Shepherd MD Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. Mayo Clin Proc 2002;77:276-82.[Abstract/Free Full Text]
• Romeo JH, Seftel AD, Madhun ZT, Aron DC Sexual function in men with diabetes type 2: association with glycemic control. J Urol 2000;163: 788-91.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sairam K., Kulinskaya E., Boustead GB, Hanbury DC, McNicholas TA Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. Br J Urol Int 2001;88:68-71.
• Rampin O. Mode of action of a new oral treatment for erectile dysfunction: Apomorphine SL. Br J Urol Int 2001;88(suppl 3):22-4.
• Eardley I. Pathophysiology of erectile dysfunction. Br J Diabetes Vasc Dis 2002;2:272-6.[Abstract/Free Full Text]
• Stief C., Padley RJ, Perdok RJ, Sleep DJ Cross-study review of the clinical efficacy of apomorphine SL 2 and 3 mg: pooled data from three placebo-controlled, fixed-dose crossover studies. Eur Urol 2002;(suppl 1):12-20.
• Hatzichristou D., Saenz de Tejada I., Sleep DJ, Perdok R. Time to erection with Uprima (apomorphine SL) 2 and 3 mg in men with erectile dysfunction (ED). Int J Impot Res 2002;13(suppl 4):S50(abstract 140).
• Chew KK, Stuckey BGA, Thompson PL Erectile dysfunction, sildenafil, and cardiovascular risk. Med J Aust 2000;172:279-83.[Web of Science][Medline] [Order article via Infotrieve]
• Adams MA, Sleep D., Perdok R., Padley R. Safety and tolerability of apomorophine SL in men with cardiovascular disorders. Eur Urol 2002;(suppl 1);28-32.
• Wagner G. Apomorphine SL (Uprima): a new treatment for the management of erectile dysfunction. Int J Impot Res 2001;13(suppl 3):S1-2.
• Dula E., Buttler S., Perdok R., Agre K. Efficacy and safety of apomorphine SL vs. placebo for erectile dysfunction in patients with coronary artery disease. J Urol 2000;163(suppl 4):(abstract 889).
• Mirone VG, Stief CG Efficacy of apomorphine SL in erectile dysfunction. Br J Urol Int 2001;88(suppl 3):25-9.
• Kirby R., Carson C., Goldstein I., Fawzy A. Epidemiology. In Erectile Dysfunction: A Clinical Guide. Oxford, UK: ISIS Medical Media, 1999;2-3.
• Dula E., Bukofzer S., Perdok R., George M. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction (ED). Eur Urol 2001;39:558-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Heaton JPW, Dean J., Sleep DJ Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. Int J Impot Res 2002;14:61-4.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Garber AJ Vascular disease and lipids in diabetes. Med Clinics No Am 1998;82(4):931-48.[CrossRef]
• Goldberg RB Cardiovascular disease in diabetic patients. Med Clinics N Am 2000;84(1):81-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Montorsi F. The role of apomorphine SL in the treatment of erectile dysfunction. Eur Urol 2002;(suppl 1):4-11.
• Fagan T., Buttler S., Marbury T., Taylor A., Edmonds A., and the SL APO Study Group. Cardiovascular safety of sublingual apomorphine SL in patients on stable doses of oral antihypertensive agents and nitrates. Am J Cardiol 2001;88:760-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 2, No. 4, 296-300 (2002)
DOI: 10.1177/14746514020020041101


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kell, P. Articles by Ralph, D. Search for Related Content Social Bookmarking                         What's this?